BNP Paribas Arbitrage SNC Has $6.60 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

BNP Paribas Arbitrage SNC decreased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 20.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 510,841 shares of the biopharmaceutical company’s stock after selling 128,347 shares during the quarter. BNP Paribas Arbitrage SNC owned approximately 0.40% of Dynavax Technologies worth $6,600,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in DVAX. Bank of America Corp DE raised its position in Dynavax Technologies by 811.6% during the first quarter. Bank of America Corp DE now owns 4,340,287 shares of the biopharmaceutical company’s stock worth $42,578,000 after acquiring an additional 3,864,170 shares in the last quarter. State Street Corp raised its position in shares of Dynavax Technologies by 36.1% in the first quarter. State Street Corp now owns 8,498,732 shares of the biopharmaceutical company’s stock valued at $92,126,000 after purchasing an additional 2,253,376 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Dynavax Technologies by 63.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,931,727 shares of the biopharmaceutical company’s stock valued at $28,759,000 after purchasing an additional 1,140,347 shares during the period. Renaissance Technologies LLC raised its position in shares of Dynavax Technologies by 64.3% in the first quarter. Renaissance Technologies LLC now owns 2,646,309 shares of the biopharmaceutical company’s stock valued at $25,960,000 after purchasing an additional 1,035,658 shares during the period. Finally, Mizuho Markets Cayman LP bought a new position in shares of Dynavax Technologies in the first quarter valued at about $7,425,000. Institutional investors and hedge funds own 99.13% of the company’s stock.

Dynavax Technologies Trading Up 1.3 %

Shares of Dynavax Technologies stock opened at $13.68 on Tuesday. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 35.08 and a beta of 1.44. The company has a quick ratio of 14.49, a current ratio of 15.40 and a debt-to-equity ratio of 0.37. Dynavax Technologies Co. has a 12-month low of $9.42 and a 12-month high of $15.15. The firm’s 50-day moving average price is $14.05 and its two-hundred day moving average price is $13.42.

Insiders Place Their Bets

In other Dynavax Technologies news, CMO Robert Janssen sold 1,755 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $15.01, for a total transaction of $26,342.55. Following the sale, the chief marketing officer now directly owns 49,925 shares in the company, valued at $749,374.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Dynavax Technologies news, CMO Robert Janssen sold 1,755 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $15.01, for a total transaction of $26,342.55. Following the sale, the chief marketing officer now directly owns 49,925 shares in the company, valued at $749,374.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO David F. Novack sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $15.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now owns 3,187 shares in the company, valued at $47,805. The disclosure for this sale can be found here. Insiders have sold 141,627 shares of company stock worth $2,092,122 over the last ninety days. Corporate insiders own 2.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. StockNews.com assumed coverage on shares of Dynavax Technologies in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. Finally, JMP Securities increased their price objective on shares of Dynavax Technologies from $25.00 to $27.00 and gave the company a “market outperform” rating in a research report on Friday, November 3rd.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.